Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C

Algeron (cepeginterferon alfa-2b) is a new pegylated form of interferon alfa containing linear polyethylene glycol (molecular weight 20 kDa). Pharmacokinetic profile of Algeron allows once weekly administration. In phase II–III study 150 treatment-naive patients with compensated liver function were randomized into 3 groups: Algeron 1,5 μg/kg/week, Algeron 2,0 μg/kg/week, and a reference group of PegIntron 1.5 μg/kg/week in combination with ribavirin 800– 1400 mg/day. Comparative ITT -analysis of early virologic response (EVR) showed absence of differences between groups in frequency of EVR. In Algeron groups (regardless of a dose – 1,5 or 2,0 μg/kg) EVR was observed in 94%, in PegIntron group – – in 88% of patients. Complete EVR (HCV RNA≤15 I I U/mL) was recorded in 88% and 84% of patients receiving Algeron 1,5 and 2,0 μg/kg, respectively, in the reference group – – in 84% of patients. There were no statistically significant differences between groups where patients received Algeron in different doses and the reference group, with or without genotype stratification. Adverse events occurring during the treatment with Algeron are dose-dependent; however, their frequency is no more than in patients receiving standard doses of PegIntron. Based on the absence of differences in efficacy and more favorable safety profile of a lower dose of the study drug, the therapeutic dose of Algeron was selected to be 1,5 μg/kg/week.

1. Lavanchy, D. The global burdgen of hepatitis C / D. Lavanchy // Liver Int. – 2009. – № 29 (suppl 1). – Р. 74–81.

2. Sheppard, C.W. Global epidemiology of hepatitis C virus infection / C.W. Sheppard, L. Finelli, M.J. Alter // Lancet Infect. Dis. 2005. – № 5. – Р. 558–567.

3. Ющук, Н.Д. Протокол диагностики и лечения больных вирусными гепатитами В и С / Н.Д. Ющук [и др.] // РЖГГК. – 2010. – № 6. – С. 5–60.

4. Reddy, K.R. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C / K.R. Reddy [et al.] // Hepatology. – 2001. – № 33 (2). – Р. 433–438.

5. Кузин, С.Н. Распространение гепатита С и отдельных генотипов вируса гепатита С в регионе с умеренной активностью эпидемического процесса / С.Н. Кузин [и др.] // Вопросы вирусологии. – 1999. – № 2. – С. 79–82.

6. Shustov, A. The prevalence, subtype distribution and molecular variability of hepatitis С virus (HCV) in the territory of Western Siberia / A. Shustov [et al.] // Xlth Intern. Congress of Virology. Sydney, Australia. – 1999. – Р. 279.

7. Быстрова, Т.Н. Характеристика репликативной формы хронического гепатита С / Т.Н. Быстрова, М.К. Абрамова, Ю.В. Михайлова // Инфекция и иммунитет. – 2012. – Т. 2, № 1–2. – С. 436.

8. Ge, D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance / D. Ge [et al.] // Nature. – 2009. – № 461. – Р. 798–401.

9. Statermayer, A.F. Impact of IL28B genotype on the early and sustained virologic response in the treatment-naïve patients with chronic hepatitis C / A.F. Statermayer [et al.] // Clin. Gastroenterol. Hepatol. – 2011. – №9. – Р. 344–350.

10. Lee, S.S. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD) / S.S. Lee [et al.] // J. Hepatol. – 2002. – № 37 (4). – Р. 500–506.

11. Marcellin, P. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) / P. Marcellin [et al.] // 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA November 2–6, 2007.

12. Богословская, Е.В. Оценка эффективности противовирусной терапии хронического гепатита С в максимально ранние сроки / Е.В. Богословская [и др.] // РЖГГК. – 2007. – № 2. – С. 36–39.